These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

269 related articles for article (PubMed ID: 22544653)

  • 1. Atypical and anaplastic meningiomas treated with bevacizumab.
    Nayak L; Iwamoto FM; Rudnick JD; Norden AD; Lee EQ; Drappatz J; Omuro A; Kaley TJ
    J Neurooncol; 2012 Aug; 109(1):187-93. PubMed ID: 22544653
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bevacizumab therapy for adults with recurrent/progressive meningioma: a retrospective series.
    Lou E; Sumrall AL; Turner S; Peters KB; Desjardins A; Vredenburgh JJ; McLendon RE; Herndon JE; McSherry F; Norfleet J; Friedman HS; Reardon DA
    J Neurooncol; 2012 Aug; 109(1):63-70. PubMed ID: 22535433
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sunitinib for atypical and anaplastic meningioma.
    Rahman A
    Lancet Oncol; 2014 Sep; 15(10):e424. PubMed ID: 25328951
    [No Abstract]   [Full Text] [Related]  

  • 4. Efficacy of adjuvant radiotherapy for atypical and anaplastic meningioma.
    Zhu H; Bi WL; Aizer A; Hua L; Tian M; Den J; Tang H; Chen H; Wang Y; Mao Y; Dunn IF; Xie Q; Gong Y
    Cancer Med; 2019 Jan; 8(1):13-20. PubMed ID: 30680963
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase II trial of sunitinib for recurrent and progressive atypical and anaplastic meningioma.
    Kaley TJ; Wen P; Schiff D; Ligon K; Haidar S; Karimi S; Lassman AB; Nolan CP; DeAngelis LM; Gavrilovic I; Norden A; Drappatz J; Lee EQ; Purow B; Plotkin SR; Batchelor T; Abrey LE; Omuro A
    Neuro Oncol; 2015 Jan; 17(1):116-21. PubMed ID: 25100872
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Kinetics of tumor size and peritumoral brain edema before, during, and after systemic therapy in recurrent WHO grade II or III meningioma.
    Furtner J; Schöpf V; Seystahl K; Le Rhun E; Rudà R; Roelcke U; Koeppen S; Berghoff AS; Marosi C; Clement P; Faedi M; Watts C; Wick W; Soffietti R; Weller M; Preusser M
    Neuro Oncol; 2016 Mar; 18(3):401-7. PubMed ID: 26354929
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intratumoral and peritumoral post-irradiation changes, but not viable tumor tissue, may respond to bevacizumab in previously irradiated meningiomas.
    Furuse M; Nonoguchi N; Kawabata S; Miyata T; Toho T; Kuroiwa T; Miyatake S
    Radiat Oncol; 2015 Jul; 10():156. PubMed ID: 26223253
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bevacizumab treatment in malignant meningioma with additional radiation necrosis. An MRI diffusion and perfusion case study.
    Boström JP; Seifert M; Greschus S; Schäfer N; Glas M; Lammering G; Herrlinger U
    Strahlenther Onkol; 2014 Apr; 190(4):416-21. PubMed ID: 24429478
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Application of bevacizumab in the management of meningiomas: a systematic review and meta-analysis.
    Hajikarimloo B; Hasanzade A; Sabbagh Alvani M; Habibi MA
    Neurosurg Rev; 2024 Sep; 47(1):692. PubMed ID: 39327340
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Metastatic Atypical and Anaplastic Meningioma: A Case Series and Review of the Literature.
    Kessler RA; Garzon-Muvdi T; Yang W; Weingart J; Olivi A; Huang J; Brem H; Lim M
    World Neurosurg; 2017 May; 101():47-56. PubMed ID: 28143726
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Brachytherapy with surgical resection as salvage treatment for recurrent high-grade meningiomas: a matched cohort study.
    Mooney MA; Bi WL; Cantalino JM; Wu KC; Harris TC; Possatti LL; Juvekar P; Hsu L; Dunn IF; Al-Mefty O; Devlin PM
    J Neurooncol; 2020 Jan; 146(1):111-120. PubMed ID: 31745706
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinicopathologic features of aggressive meningioma emphasizing the role of radiotherapy in treatment.
    Engenhart-Cabillic R; Farhoud A; Sure U; Heinze S; Henzel M; Mennel HD; Bertalanffy H
    Strahlenther Onkol; 2006 Nov; 182(11):641-6. PubMed ID: 17072521
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase II study of imatinib mesylate for recurrent meningiomas (North American Brain Tumor Consortium study 01-08).
    Wen PY; Yung WK; Lamborn KR; Norden AD; Cloughesy TF; Abrey LE; Fine HA; Chang SM; Robins HI; Fink K; Deangelis LM; Mehta M; Di Tomaso E; Drappatz J; Kesari S; Ligon KL; Aldape K; Jain RK; Stiles CD; Egorin MJ; Prados MD
    Neuro Oncol; 2009 Dec; 11(6):853-60. PubMed ID: 19293394
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Re-irradiation of anaplastic meningioma: higher dose and concomitant Bevacizumab may improve progression-free survival.
    Haisraely O; Taliansky A; Sivan M; Lawerence Y
    Radiat Oncol; 2024 Oct; 19(1):135. PubMed ID: 39358739
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bevacizumab treatment for meningiomas in NF2: a retrospective analysis of 15 patients.
    Nunes FP; Merker VL; Jennings D; Caruso PA; di Tomaso E; Muzikansky A; Barker FG; Stemmer-Rachamimov A; Plotkin SR
    PLoS One; 2013; 8(3):e59941. PubMed ID: 23555840
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bevacizumab in refractory higher-grade and atypical meningioma: the current state of affairs.
    Dasanu CA; Alvarez-Argote J; Limonadi FM; Codreanu I
    Expert Opin Biol Ther; 2019 Feb; 19(2):99-104. PubMed ID: 30556741
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of bevacizumab on intracranial meningiomas in patients with neurofibromatosis type 2 - a retrospective case series.
    Alanin MC; Klausen C; Caye-Thomasen P; Thomsen C; Fugleholm K; Poulsgaard L; Lassen U; Mau-Sorensen M; Hofland KF
    Int J Neurosci; 2016 Nov; 126(11):1002-6. PubMed ID: 26365467
    [TBL] [Abstract][Full Text] [Related]  

  • 18. WHO grade II and III meningiomas: a study of prognostic factors.
    Durand A; Labrousse F; Jouvet A; Bauchet L; Kalamaridès M; Menei P; Deruty R; Moreau JJ; Fèvre-Montange M; Guyotat J
    J Neurooncol; 2009 Dec; 95(3):367-375. PubMed ID: 19562258
    [TBL] [Abstract][Full Text] [Related]  

  • 19. "Malignancy" in meningiomas: a clinicopathologic study of 116 patients, with grading implications.
    Perry A; Scheithauer BW; Stafford SL; Lohse CM; Wollan PC
    Cancer; 1999 May; 85(9):2046-56. PubMed ID: 10223247
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Microvascularization and expression of VEGF and its receptors in recurring meningiomas: pathobiological data in favor of anti-angiogenic therapy approaches.
    Preusser M; Hassler M; Birner P; Rudas M; Acker T; Plate KH; Widhalm G; Knosp E; Breitschopf H; Berger J; Marosi C
    Clin Neuropathol; 2012; 31(5):352-60. PubMed ID: 22541785
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.